|Aleksandra Szczepankiewicz, Anna Bręborowicz, Paulina Sobkowiak, Anna Popiel|
Introduction. The course of asthma and response to antiasthmatic treatment are very heterogenous in the population of patients. One of the factors underlying this heterogeneity is its genetic component. Genetic factors can also modify bronchodilator response to β2-agonists that may be subsequently impaired by chronic administration of those drugs, which is particularly dangerous in asthma exacerbations. On the other hand, the influence of chronic exposure to β2-agonists on bronchodilator response to anticholinergic agents is poorly described.
Aim of the study. The aim of the study was to analyse the relationship between ADRB2 and CHRM2 genes polymorphism and asthma severity in asthmatic children, as well as with bronchodilator response to an inhaled β2-agonist and an anticholinergic agent.
Material and methods. 99 asthmatic children in the age range of 6 to 18 years old treated with inhaled corticosteroids and LABAs for at least 3 months participated in the study. In all patients we performed spirometry and bronchodilator response to salbutamol and ipratropium bromide after LABA withdrawal. Polymorphism of ADRB2 and CHRM2 genes was analyzed with the PCR-RFLP.
Results. We observed an association of moderate asthma with the Gly/Gly genotype of Arg16Gly ADRB2 gene polymorphism. We did not find a relationship for the other polymorphisms. The bronchodilator response to both drugs was comparable (slightly better for salbutamol), and the range of FEV1 changes did not differ significantly in patients with particular genotypes of ADRB2 and CHRM2 genes.
Conclusions. The present study confirmed an association of Arg16Gly ADRB2 gene polymorphism and asthma severity. Polymorphism of ADRB2 and CHRM2 genes is not useful in the identification of patients with specific response to anticholinergic drugs.
keywords: astma, polimorfizm, gen receptora β2-adrenergicznego, gen receptora muskarynowego typu 2, farmakogenetyka, asthma, polymorphism, β2-adrenergic receptor gene, muscarinic type receptor gene, pharmacogenetics
pages: from 45 to 54
|estimated time of download (413 kB)|